L-fmau for the treatment of hepatitis delta viral infection

European treating main the method of hepatitis D virus infection, comprising the alleviation of quantity's a nucleoside or the nucleoside analog, wherein or a medicine, or a medicinal salt, they can or the type of S1 antigen host's hepatitis B and end of the front lower 100 times of the therapeutic or more, or not more than each millilitre 1 microgram. The is preferred embodiment, wherein the nucleoside is L-FMAU or a pharmaceutically-acceptable salt or; the medicine.